OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program

Conclusions Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.

http://cep.sagepub.com/cgi/content/abstract/36/9/899?rss=1

Source: Cephalalgia - July 21, 2016 Category: Neurology Authors: Lipton, R. B., Rosen, N. L., Ailani, J., DeGryse, R. E., Gillard, P. J., Varon, S. F. Tags: Original Articles Source Type: research